William Blair reiterated their outperform rating on shares of Simulations Plus (NASDAQ:SLP – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. William Blair also issued estimates for Simulations Plus’ Q1 2026 earnings at $0.19 EPS.
A number of other brokerages have also recently issued reports on SLP. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday. BTIG Research lowered their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. KeyCorp started coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. Finally, JMP Securities began coverage on Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.
Get Our Latest Stock Report on Simulations Plus
Simulations Plus Price Performance
Simulations Plus (NASDAQ:SLP – Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The company’s revenue for the quarter was up 19.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.18 earnings per share. On average, equities research analysts expect that Simulations Plus will post 1.11 earnings per share for the current fiscal year.
Insider Transactions at Simulations Plus
In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the sale, the director now owns 3,501,592 shares in the company, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 60,750 shares of company stock worth $1,905,655 over the last three months. 20.90% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Simulations Plus
Hedge funds have recently made changes to their positions in the stock. Tributary Capital Management LLC raised its holdings in Simulations Plus by 54.7% in the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock valued at $10,425,000 after acquiring an additional 115,122 shares in the last quarter. Silvercrest Asset Management Group LLC acquired a new stake in shares of Simulations Plus during the 1st quarter worth approximately $4,717,000. Royce & Associates LP increased its position in shares of Simulations Plus by 28.8% during the third quarter. Royce & Associates LP now owns 237,416 shares of the technology company’s stock valued at $7,602,000 after purchasing an additional 53,092 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Simulations Plus by 10.1% in the second quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after purchasing an additional 37,992 shares in the last quarter. Finally, Congress Asset Management Co. lifted its position in Simulations Plus by 22.5% in the third quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock worth $6,613,000 after purchasing an additional 37,914 shares during the period. Institutional investors own 78.08% of the company’s stock.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
- Five stocks we like better than Simulations Plus
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MGM vs. Las Vegas Sands: Which Casino Stock Is the Better Bet?
- Bank Stocks – Best Bank Stocks to Invest In
- What a Trump Win Looks Like for the Market Now and Into 2025
- Stock Average Calculator
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.